---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-243039"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2025-10-20T23:59:59+00:00"
generated_at: "2026-05-17T03:13:39.703709+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Viridian Therapeutics secures up to $600M via royalty sale and debt facility

## Summary
- DRI Healthcare pays $55M upfront for U.S. revenue rights; up to $300M total tied to VRDN-003 milestones and FDA approval.
- Tiered royalties on veligrotug/VRDN-003 net sales: 7.5% up to $600M, then declining to zero above $2B.
- Hercules Capital provides $300M term loan facility; $50M drawn at close, with tranches up to $300M depending on milestones.
- Loan bears interest at prime+1.45% (floor 8.95%, cap 9.45%), maturity 2030, interest-only through 2029/2030.
- Combined financing strengthens balance sheet for pivotal clinical trials and pre-commercial activities.

## SEC filing metadata
- accession: 0001193125-25-243039
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2025-10-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312525243039/0001193125-25-243039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312525243039/d20179d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-243039
- JSON: https://secwatch.observer/filing/0001193125-25-243039.json
- Plain text: https://secwatch.observer/filing/0001193125-25-243039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.